Indrayani Biotech Peer Comparison

BSE: 526445

₹7.78

₹-0.36 (-4.42%)

As on 09-Nov-2026IST

Market cap

₹42 Cr

Revenue (TTM)

₹181 Cr

P/E Ratio

20

P/B Ratio

0.5

Div. Yield

0 %

Edit

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Market cap (₹ Cr)	42	8,876	327	213	62
Revenue (₹ Cr)	181	22,882	87	434	71
Net Profit (₹ Cr)	2.66	422.61	12.10	17.44	-6.24
Net Margin (%)	1.42	1.84	13.69	3.90	2.15
RoE (%)	2.82	7.66	10.07	6.80	-115.30
Price to Earnings	20.00	21.00	27.04	12.24	--
Price-To-Book	0.49	1.46	2.58	0.82	28.78

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Operating Revenue	181.45	22,882.35	86.50	433.83	71.28
Total Income	187.39	22,949.88	88.38	446.74	73.29
Total Expenditure	169.74	21,442.20	66.52	403.95	65.73
EBITDA	11.70	1,440.15	19.98	29.89	5.55
Depreciation	5.55	204.78	4.44	10.72	3.67
EBIT	6.16	1,235.37	15.55	19.17	1.88
Interest	11.27	695.68	0.39	13.08	2.24
Other Income	5.94	67.53	1.89	12.91	2.01
Exceptional Items	0.00	-58.78	-0.60	0.00	0.00
Profit before Tax	0.82	548.44	16.44	18.99	1.65
Provision for Tax	-1.84	125.83	4.35	1.55	0.08
Profit after Tax	2.66	422.61	12.10	17.44	1.57

Liabilities (₹ Cr)

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Shareholder's Funds	72.89	6,091.35	126.79	257.94	0.68
Minority Interest	-0.56	0.00	0.00	0.00	0.00
Non-Current Liabilities	58.36	1,039.42	2.39	58.41	10.44
Current Liabilities	92.98	17,687.49	14.07	236.55	59.03
Total Liabilities	253.43	25,133.45	134.69	567.57	68.45

Assets (₹ Cr)

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Non-Current Assets	89.67	2,109.57	66.35	277.80	35.56
Current Assets	158.72	21,822.60	66.01	249.09	31.18
Total Assets	253.43	25,133.45	134.69	567.57	68.45
Total Debt*	--	5,103.23	2.43	148.60	39.12
Net Current Assets	65.74	4,135.11	51.95	12.55	-27.85
Contingent Liabilities	--	188.22	2.67	16.95	4.61

Cashflow (₹ Cr)

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Cash From Operating Activities	--	-414.12	12.08	14.25	0.66
Cash Flow from Investing Activities	--	-241.80	-10.09	-8.24	-9.76
Cash from Financing Activities	--	510.97	-5.36	-3.75	9.44
Net Cash Inflow / Outflow	--	-144.95	-3.37	2.26	0.34

Ratios

Profitability Ratios

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
ROCE (%)	--	16.35	11.43	6.08	-0.48
ROE (%)	2.82	7.66	10.07	6.80	-115.30
ROA (%)	1.02	1.75	8.73	3.27	2.32
EBIT Margin (%)	3.39	5.40	17.97	4.42	2.63
Net Margin (%)	1.42	1.84	13.69	3.90	2.15
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Revenue Growth (%)	41.97	-1.94	17.03	-2.88	21.98
EBIT Growth (%)	475.77	-17.94	67.38	-4.16	-43.68
Net Profit Growth (%)	139.09	-38.13	51.90	-43.90	-43.22
EPS Growth (%)	127.87	-31.28	57.55	-15.97	-251.12
Book Value Growth (%)	--	15.19	7.79	5.20	-84.21

Valuation Ratios

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Price / Earnings	16.91	18.91	26.07	12.24	-35.84
Price / Book Value	0.49	1.46	2.58	0.82	28.78
Dividend Yield (%)	0.00	1.65	0.36	0.00	0.00
EV/EBITDA	3.22	9.35	15.51	12.01	18.07
Market Cap (₹ Cr)	35.79	13,619.11	131.05	172.48	49.91

Solvency Ratios

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Debt to Equity	0.79	0.11	0.01	0.13	10.20
Short term debt to equity ratio	--	0.68	--	0.41	14.97
Current Ratio	1.71	1.23	4.69	1.05	0.53
Quick Ratio	1.30	1.14	3.43	0.60	0.38
Interest Coverage	1.07	1.79	43.06	2.45	1.74

Operating Efficiency Ratios

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Debtors to sales (%)	32.28	24.51	24.65	14.56	21.93
Asset Turnover	0.70	0.94	0.62	0.81	1.05
Receivable days	--	89.48	87.30	52.78	79.88
Inventory Days	--	20.76	61.62	83.71	57.53
Payable days	--	238.84	135.35	179.84	149.50
Cash Conversion Cycle	--	-128.60	13.57	-43.36	-12.09

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.